Skip to main content

Non-Antibiotic UTI Prevention

Non-antibiotic strategies sit at the front of the recurrent-UTI prevention ladder per the AUA/CUA/SUFU 2022 guideline, the WikiGuidelines 2024 consensus, and the AGS Beers alternatives document. The rationale is identical across documents: comparable efficacy for many options, meaningfully lower resistance pressure, and better long-term tolerability than daily antibiotic prophylaxis.[1][2][3] A 2025 network meta-analysis of 50 RCTs (n = 10,495) comparing 14 non-antibiotic interventions found D-mannose (RR 0.34), vaccines (RR 0.65), probiotics (RR 0.69), and cranberry (RR 0.72) all significantly reduced UTI incidence vs placebo with no increase in adverse events — but as the individual-agent sections below show, the D-mannose network signal is not reproduced in the largest primary-care RCT, and head-to-head evidence is still evolving.[4]

This article is the prescribing-detail deep-dive for each modality. For the stepwise management framework, see UTI suppressive & prophylactic therapy; for treatment of active infection, see UTI treatment antibiotics.

Vaginal estrogen​

AUA/CUA/SUFU 2022 — Moderate Recommendation, Grade B: "In peri- and post-menopausal women with rUTIs, clinicians should recommend vaginal estrogen therapy to reduce the risk of future UTIs if there is no contraindication to estrogen therapy." Updated meta-analysis incorporating a new study showed RR 0.58 (95% CI 0.39–0.87) for UTI recurrence with vaginal estrogen.[1]

Mechanism​

GSM is a root cause of rUTI in postmenopausal women. Estrogen deprivation leads to vaginal and urethral atrophy, loss of Lactobacillus colonization, rising vaginal pH, and increased uropathogen colonization — vaginal estrogen reverses all three.[5]

Formulations and dosing​

FormulationTypical regimenPractical notes
Estradiol cream (0.01%)0.5–1 g intravaginally 2–3×/weekMost flexible dosing; messy
Estradiol tablets (10 µg)One tablet intravaginally 2×/week after loadingMinimal systemic absorption; patient-preferred
Estradiol ring (Estring, 7.5 µg/24 h)One ring every 90 daysBest adherence; insert-and-forget
Estriol cream / ring (not FDA-approved in US)0.5 mg 2×/weekThe Raz-Stamm trial agent; available in Europe
DHEA (prasterone) 6.5 mg vaginalNightlyNot formally studied for rUTI but treats GSM

Efficacy​

  • Raz & Stamm 1993 (landmark RCT, intravaginal estriol) — cumulative infection-free proportion dramatically higher vs placebo over 8 months; the trial that established the modality[6]
  • Chen 2021 meta-analysis (5 RCTs, n = 1,936) — vaginal estrogen reduced rUTI with RR 0.42 (95% CI 0.30–0.59); oral/systemic estrogen showed no benefit (RR 1.11; 95% CI 0.92–1.35) and should not be used for UTI prevention[7]
  • Tan-Kim 2023 (retrospective, n = 5,638 women prescribed vaginal estrogen for rUTI) — 51.9% reduction in UTI frequency in the year following prescription (3.9 → 1.8 episodes/year; p < 0.001) — the best real-world dataset[8]

Safety​

  • Local AEs: vaginal irritation, burning, or spotting in 6–20%; systemic absorption at labeled doses is minimal[9]
  • Breast cancer survivors: ACOG clinical consensus permits vaginal estrogen in appropriately counseled survivors when non-hormonal options have failed, with preference for ultra-low-dose estradiol (10 µg) or DHEA; coordinate with oncology
  • Endometrial safety: prolonged daily dosing can cause mild endometrial stimulation; the 2×/week maintenance regimen is the standard to minimize this

See GSM for the comprehensive genitourinary syndrome of menopause framework.

Methenamine hippurate​

Mechanism: methenamine hydrolyzes to formaldehyde in acidic urine (pH <6), producing non-specific bacteriostasis. Because the active species forms in the bladder, it avoids systemic antimicrobial pressure. Optimal efficacy requires urinary acidification — concurrent ascorbic acid (1 g BID) or cranberry is sometimes recommended, though data for the combined approach are limited.[10]

Dosing​

  • Standard regimen: 1 g PO BID
  • Onset of prophylactic effect: ~1–2 weeks
  • Duration: an initial 6–12-month course is common; reassess periodically

Efficacy​

  • ALTAR trial (Harding 2022, n = 240, multicenter open-label non-inferiority RCT) — methenamine non-inferior to daily low-dose antibiotics (nitrofurantoin 50–100 mg, trimethoprim 100 mg, or cefalexin 250 mg) at 12 months (1.38 vs 0.89 episodes/person-year; within the 1-episode non-inferiority margin). Antibiotic resistance in perineal E. coli was significantly higher in the antibiotic arm (72% vs 56%; p = 0.05)[10][11]
  • ImpresU trial (Heltveit-Olsen 2025, n = 289 women ≥70 y, triple-blind placebo-controlled phase IV) — 25% reduction in antibiotic-treated UTIs at 6 months (IRR 0.75; 95% CI 0.57–1.0; p = 0.049); rebound increase in UTI rate after discontinuation (IRR 1.7; p < 0.05)[12]
  • Davidson 2024 systematic review (7 studies) — consistent support across populations and clinical settings[13]

Safety​

  • Generally well tolerated
  • GI upset most common
  • Avoid in renal insufficiency (concern about reduced urinary excretion and theoretical systemic formaldehyde exposure) and in severe hepatic impairment
  • Contraindicated in gout and severe dehydration
  • Not effective against urea-splitting organisms (Proteus, Ureaplasma) — these alkalinize urine and block formaldehyde generation

Cranberry products​

Mechanism: proanthocyanidins (PAC) — especially A-type PACs — inhibit P-fimbriae-mediated adherence of uropathogenic E. coli to uroepithelial cells.

Dose — PAC content matters more than form​

  • WikiGuidelines 2024 recommends products containing ≥36 mg PAC per day for women, children, and people susceptible to UTI after interventions.[2]
  • Juice, capsules, and whole-fruit powder have all been studied; standardized capsule with declared PAC content is the most reproducible form
  • Typical commercial dosing: 500 mg whole-cranberry powder or 36–72 mg PAC capsule daily

Efficacy​

  • Beerepoot 2013 meta-analysis — pooled RR 0.53 (95% CI 0.33–0.83)[9]
  • Stonehouse 2025 (multicenter, double-blind, placebo-controlled, n = 150 women with rUTI) — whole cranberry fruit powder 500 mg/day reduced culture-confirmed UTI by 52% (aRR 0.48; 95% CI 0.26–0.87; p = 0.01), delayed time to first UTI (HR 0.36; p = 0.01), and reduced total episodes (IRR 0.41; p = 0.01)[14]
  • German guideline review pooled RR 0.74 (95% CI 0.5–0.99) for cranberry juice specifically[15]

Safety​

Well tolerated; no increase in adverse events vs placebo.[14] Theoretical warfarin interaction is inconsistent in the literature — monitor INR if starting cranberry in a patient on warfarin.

D-mannose​

Mechanism: binds type 1 fimbriae on E. coli, blocking adherence to urothelial mannose receptors. Pharmacologically attractive; clinically underwhelming in recent rigorous data.

Evidence — conflicting​

  • Han 2025 network meta-analysis — largest effect size of any non-antibiotic intervention (RR 0.34; 95% CI 0.21–0.56), driven by smaller / older studies[4]
  • MERIT RCT (Hayward 2024, JAMA Intern Med, n = 598 women in primary care) — no significant benefit: 51.0% vs 55.7% with a medically attended UTI over 6 months (adjusted HR 0.92; 95% CI 0.73–1.16)[16]
  • WikiGuidelines 2024 concludes insufficient evidence to recommend for or against[2]

Dosing (when used despite the equivocal evidence)​

Typical regimen 2 g PO once daily or 1 g BID, dissolved in water. Minimal AEs (occasional diarrhea at higher doses). Cannot be strongly recommended as a primary strategy given MERIT.

Hydration (≥1.5 L/day increase)​

Hooton 2018 (JAMA Intern Med, RCT, n = 140 premenopausal women with rUTI and low baseline fluid intake) — adding 1.5 L of water daily cut recurrences by ~50% over 12 months (1.7 vs 3.2 episodes; p < 0.001) and reduced antimicrobial regimen use comparably.[17]

  • Low-risk, zero-resistance-pressure intervention
  • Confirmatory studies in postmenopausal women and patients with neurogenic bladder are awaited, but the intervention is cheap and reasonable to recommend broadly

Probiotics​

Heterogeneous evidence across strains, routes, and populations. The Han 2025 network meta-analysis found RR 0.69 (95% CI 0.50–0.94) with the strongest signal in pediatric subgroups (RR 0.50; 95% CI 0.28–0.89).[4] WikiGuidelines 2024 found inconclusive evidence and makes no formal recommendation.[2]

  • Most studied strains: vaginal Lactobacillus crispatus CTV-05 (Lactin-V), L. rhamnosus GR-1, L. reuteri RC-14
  • Route matters: vaginal delivery plausibly more directly relevant than oral for urinary colonization
  • Reasonable adjunct to vaginal estrogen in selected postmenopausal patients; not a stand-alone first-line option

Immunoprophylaxis​

None of these are FDA-approved in the US, but they are part of the global rUTI armamentarium and increasingly appear in patient-initiated queries.

OM-89 (Uro-Vaxom) — oral E. coli lysate​

  • Bauer 2005 RCT (n = 453, multicenter double-blind) — 34% reduction in UTI rate (0.84 vs 1.28 episodes; p < 0.001) with favorable safety[18]
  • Beerepoot 2013 meta-analysis — pooled RR 0.61 (95% CI 0.48–0.78)[9]
  • Volontè 2025 systematic review — confirmed reduced recurrence, good tolerability, and reduced antibiotic use[19]
  • Latin American consensus — Grade A recommendation[20]
  • Regimen: 6 mg PO once daily for 3 months (re-courses available)

MV140 (Uromune) — sublingual polybacterial spray​

  • Whole-cell heat-inactivated E. coli, K. pneumoniae, P. vulgaris, E. faecalis
  • Lorenzo-Gómez 2021 prospective cohort in frail elderly women — 7- to 40-fold reduction in UTI episodes after a 3-month course with improved QoL[21]
  • Large RCTs ongoing

Urovac — vaginal mucosal vaccine​

  • Modest reduction (RR 0.75; 95% CI 0.63–0.89); booster immunization extends time to reinfection[22]

Aziminia 2019 systematic review — 10 RCTs, n = 1,537​

Pooled RR 0.74 (95% CI 0.67–0.81) for vaccines vs placebo; evidence quality low with substantial heterogeneity.[22]

Vitamin D​

Mechanism: vitamin D induces cathelicidin (LL-37), a cationic antimicrobial peptide expressed by bladder urothelium and neutrophils.[23]

Evidence​

  • Jorde 2016 (RCT, n = 511 prediabetic subjects) — vitamin D3 20,000 IU/week for 5 years significantly reduced UTI reports vs placebo (18 vs 34 subjects; p < 0.05)[24]
  • D-Health Trial (Pham 2022, n = 21,315 older Australian adults) — modest reduction in antibiotic prescriptions with vitamin D supplementation, stronger in those with insufficient baseline levels[25]
  • Han 2025 network meta-analysis — RR 0.46 (95% CI 0.27–0.81) in the long follow-up subgroup (≥1 year)[4]

Not yet in major rUTI guideline recommendations. Reasonable as adjunct in patients with measured insufficiency — concurrent correction of a common deficiency that may also benefit bone and immune health.

Intravesical GAG replenishment (HA ± CS)​

Intravesical hyaluronic acid ± chondroitin sulfate is intended to restore the protective GAG layer of the bladder urothelium, reducing bacterial adherence and neurogenic inflammation. Primarily European practice; primarily deployed in refractory rUTI when non-antibiotic and antibiotic strategies have failed.

Evidence​

  • Damiano 2011 placebo-controlled RCT (n = 57) — HA-CS instillation reduced UTI rate by 86.6% vs 9.6% placebo (p = 0.0002) and extended time to first recurrence (185 vs 53 days; p < 0.05)[26]
  • Corona 2025 meta-analysis — HA-CS reduced infection rates vs placebo or standard care (OR 0.42; 95% CI 0.25–0.49; p < 0.001)[27]
  • Goddard 2018 systematic review + meta-analysis — HA ± CS decreased UTI rate per patient-year (pooled MD −2.56; 95% CI −3.86 to −1.26; p < 0.001)[28]

Practical notes​

  • Typical regimen: weekly instillation × 4, then monthly maintenance; protocol varies by product
  • Commercial products include iAluril (HA-CS), Cystistat (HA), Uracyst (CS)
  • Cross-covered in detail in Intravesical IC/BPS agents — same molecules used for bladder pain syndrome

Intravesical aminoglycoside instillation​

For refractory rUTI, intravesical gentamicin or amikacin — instilled as part of CIC regimens in neurogenic patients or through a Foley / suprapubic in non-neurogenic — has the strongest meta-analytic effect size among intravesical modalities.

  • Kwon 2026 systematic review + meta-analysis — intravesical aminoglycoside instillation produced the most marked reduction in recurrence among intravesical therapies (pooled IRR 0.23; 95% CI 0.15–0.37), with consistent benefit across neurogenic and non-neurogenic populations. Serum aminoglycoside levels were undetectable where measured; adverse events were mild and local[29]

Practical notes​

  • Typical regimen: gentamicin 30 mg in 50 mL normal saline instilled nightly, retained as long as tolerated; alternative amikacin 500 mg in 50 mL
  • No meaningful systemic absorption from intact urothelium — safety profile is excellent
  • Resistance can emerge; periodic urine cultures to monitor organism shift
  • Best suited to patients already doing CIC — delivery is straightforward; non-CIC patients require intermittent catheterization for each dose, which limits adherence

Behavioral modifications​

RCT evidence is limited, but these measures are low-risk and universally recommended:[6][15][17]

  • Post-coital voiding — widely recommended despite limited direct evidence
  • Avoid delaying urination — reduces bacterial dwell time
  • Wipe front-to-back — reduces fecal-perineal contamination
  • Avoid spermicides and diaphragms — associated with increased UTI risk in observational studies
  • Review contraceptive method with patients who develop rUTI after starting spermicide use

Evidence Summary​

InterventionStrength of evidenceEffect sizeGuideline status
Vaginal estrogenModerate (meta-analysis of RCTs)RR 0.42–0.58AUA Moderate / Grade B[1][7]
Methenamine hippurateModerate (non-inferiority RCT + placebo-controlled phase IV RCT)Non-inferior to daily antibiotics; 25% vs placeboAUA-endorsed alternative; WikiGuidelines recommended[10][12]
Cranberry (≥36 mg PAC)Moderate (multiple RCTs)RR 0.48–0.72AUA Conditional / Grade C; WikiGuidelines recommended[1][2][14]
Hydration +1.5 L/dayLow (single RCT)~50% reductionWikiGuidelines recommended[17]
D-mannoseConflicting (network meta positive; largest RCT negative)RR 0.34 vs nullWikiGuidelines insufficient evidence[4][16]
ProbioticsLow / inconclusiveRR 0.69WikiGuidelines inconclusive[4]
OM-89 (Uro-Vaxom)Moderate (multiple RCTs)RR 0.61Latin American Grade A; not FDA-approved[9][18][19]
MV140 (Uromune)Low (cohort)7–40× reductionOngoing RCTs; not FDA-approved[21]
Vitamin DLow (limited RCTs)RR 0.46 in long-follow-up subgroupNot in major guidelines[4][24]
Intravesical HA ± CSLow–moderate (small RCTs, meta-analysis)OR 0.42; MD −2.56/pyRefractory-rUTI option (mainly European)[27][28]
Intravesical aminoglycosidesLow–moderate (meta-analysis)IRR 0.23Refractory-rUTI option, strongest intravesical signal[29]
Behavioral modificationsVery low (observational)Not quantifiableUniversally recommended

Clinical Positioning​

  • Vaginal estrogen is first-line in postmenopausal women with rUTI regardless of whether GSM symptoms are the presenting complaint — the 2023 Tan-Kim real-world data (51.9% reduction, n = 5,638) and Chen meta-analysis (RR 0.42) are the anchor evidence.[7][8]
  • Systemic estrogen has no role in UTI prevention — use vaginal routes only.[7]
  • Methenamine hippurate is the highest-yield non-antibiotic oral agent and is non-inferior to daily antibiotics (ALTAR) with better resistance footprint.[10][11]
  • Cranberry works if the product has ≥36 mg PAC. Don't rely on cocktail juice — use a declared-PAC-content capsule or whole-fruit powder.[2][14]
  • D-mannose is no longer routinely recommended. The MERIT primary-care RCT is the largest, most rigorous, and negative.[16]
  • Add 1.5 L/day of water in every rUTI patient who is not volume-restricted. Cheap, zero-resistance, ~50% recurrence reduction in Hooton's RCT.[17]
  • Immunoprophylaxis (OM-89, MV140) is legitimate where available; not FDA-approved in the US but has Grade A support in Latin America and accumulating European evidence.[19][20][21]
  • Vitamin D is a reasonable adjunct in patients with measured insufficiency — biologically plausible (cathelicidin induction) with modest accumulating signal.[4][23][24]
  • Intravesical therapy (HA/CS, aminoglycoside) is for refractory rUTI — escalate to this tier when oral non-antibiotics and appropriate antibiotic strategies have failed. Intravesical aminoglycoside has the strongest meta-analytic signal (IRR 0.23) in the 2026 Kwon review.[29]
  • Always layer behavioral measures — post-coital voiding, spermicide avoidance, front-to-back wiping — on top of any pharmacologic strategy.

See Also​

References​

1. Anger JT, Bixler BR, Holmes RS, et al. "Updates to recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline." J Urol. 2022;208(3):536–541. doi:10.1097/JU.0000000000002860

2. Nelson Z, Aslan AT, Beahm NP, et al. "Guidelines for the prevention, diagnosis, and management of urinary tract infections in pediatrics and adults: a WikiGuidelines group consensus statement." JAMA Netw Open. 2024;7(11):e2444495. doi:10.1001/jamanetworkopen.2024.44495

3. Steinman MA. "Alternative treatments to selected medications in the 2023 American Geriatrics Society Beers Criteria." J Am Geriatr Soc. 2025;73(9):2657–2677. doi:10.1111/jgs.19500

4. Han Z, Yi X, Li J, Liao D, Ai J. "Nonantibiotic prophylaxis for urinary tract infections: a network meta-analysis of randomized controlled trials." Infection. 2025;53(2):535–546. doi:10.1007/s15010-024-02357-z

5. Buck ES, Lukas VA, Rubin RS. "Effective prevention of recurrent UTIs with vaginal estrogen: pearls for a urological approach to genitourinary syndrome of menopause." Urology. 2021;151:31–36. doi:10.1016/j.urology.2020.05.058

6. Raz R, Stamm WE. "A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections." N Engl J Med. 1993;329(11):753–756. doi:10.1056/NEJM199309093291102

7. Chen YY, Su TH, Lau HH. "Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials." Int Urogynecol J. 2021;32(1):17–25. doi:10.1007/s00192-020-04397-z

8. Tan-Kim J, Shah NM, Do D, Menefee SA. "Efficacy of vaginal estrogen for recurrent urinary tract infection prevention in hypoestrogenic women." Am J Obstet Gynecol. 2023;229(2):143.e1–143.e9. doi:10.1016/j.ajog.2023.05.002

9. Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G. "Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials." J Urol. 2013;190(6):1981–1989. doi:10.1016/j.juro.2013.04.142

10. Harding C, Mossop H, Homer T, et al. "Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open-label, randomised, non-inferiority trial (ALTAR)." BMJ. 2022;376:e068229. doi:10.1136/bmj-2021-0068229

11. Harding C, Chadwick T, Homer T, et al. "Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT." Health Technol Assess. 2022;26(23):1–172. doi:10.3310/QOIZ6538

12. Heltveit-Olsen SR, Arnljots ES, Sundvall PD, et al. "Methenamine hippurate as prophylaxis for recurrent urinary tract infections in older women — a triple-blind, randomised, placebo-controlled, phase IV trial (ImpresU)." Clin Microbiol Infect. 2025. doi:10.1016/j.cmi.2025.07.006

13. Davidson SM, Brown JN, Nance CB, Townsend ML. "Use of methenamine for urinary tract infection prophylaxis: systematic review of recent evidence." Int Urogynecol J. 2024;35(3):483–489. doi:10.1007/s00192-024-05726-2

14. Stonehouse W, Benassi-Evans B, Bednarz J, Vincent AD. "Whole cranberry fruit powder supplement reduces the incidence of culture-confirmed urinary tract infections in females with a history of recurrent urinary tract infection: a 6-month multicenter, randomized, double-blind, placebo-controlled trial." Am J Clin Nutr. 2025;121(4):932–941. doi:10.1016/j.ajcnut.2025.01.022

15. Schmiemann G, Kranz J, Mandraka F, et al. "The diagnosis, treatment, and prevention of recurrent urinary tract infection." Dtsch Arztebl Int. 2024;121(11):373–382. doi:10.3238/arztebl.m2024.0068

16. Hayward G, Mort S, Hay AD, et al. "D-mannose for prevention of recurrent urinary tract infection among women: a randomized clinical trial (MERIT)." JAMA Intern Med. 2024;184(6):619–628. doi:10.1001/jamainternmed.2024.0264

17. Hooton TM, Vecchio M, Iroz A, et al. "Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections: a randomized clinical trial." JAMA Intern Med. 2018;178(11):1509–1515. doi:10.1001/jamainternmed.2018.4204

18. Bauer HW, Alloussi S, Egger G, et al. "A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections." Eur Urol. 2005;47(4):542–548. doi:10.1016/j.eururo.2004.12.009

19. Volontè S, De Vicari D, Cola A, Barba M, Frigerio M. "Efficacy and safety of Uro-Vaxom in urinary tract infection prevention: a systematic literature review." J Clin Med. 2025;14(11):3836. doi:10.3390/jcm14113836

20. Haddad JM, Ubertazzi E, Cabrera OS, et al. "Latin American consensus on uncomplicated recurrent urinary tract infection — 2018." Int Urogynecol J. 2020;31(1):35–44. doi:10.1007/s00192-019-04079-5

21. Lorenzo-Gómez MF, Padilla-Fernández B, Flores-Fraile J, et al. "Impact of whole-cell bacterial immunoprophylaxis in the management of recurrent urinary tract infections in the frail elderly." Vaccine. 2021;39(42):6308–6314. doi:10.1016/j.vaccine.2021.08.093

22. Aziminia N, Hadjipavlou M, Philippou Y, et al. "Vaccines for the prevention of recurrent urinary tract infections: a systematic review." BJU Int. 2019;123(5):753–768. doi:10.1111/bju.14606

23. Hertting O, Holm Å, Lüthje P, et al. "Vitamin D induction of the human antimicrobial peptide cathelicidin in the urinary bladder." PLoS One. 2010;5(12):e15580. doi:10.1371/journal.pone.0015580

24. Jorde R, Sollid ST, Svartberg J, et al. "Prevention of urinary tract infections with vitamin D supplementation 20,000 IU per week for five years. Results from an RCT including 511 subjects." Infect Dis (Lond). 2016;48(11–12):823–828. doi:10.1080/23744235.2016.1201853

25. Pham H, Waterhouse M, Baxter C, et al. "Vitamin D supplementation and antibiotic use in older Australian adults: an analysis of data from the D-Health Trial." J Infect Dis. 2022;226(6):949–957. doi:10.1093/infdis/jiac279

26. Damiano R, Quarto G, Bava I, et al. "Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial." Eur Urol. 2011;59(4):645–651. doi:10.1016/j.eururo.2010.12.039

27. Corona G, Capogrosso P, Baldini S, et al. "Hyaluronic acid and chondroitin sulphate instillation in chronic bladder diseases: a meta-analysis." BJU Int. 2025. doi:10.1111/bju.70016

28. Goddard JC, Janssen DAW. "Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta-analysis." Int Urogynecol J. 2018;29(7):933–942. doi:10.1007/s00192-017-3508-z

29. Kwon M, Ahmad A, Lott N, Blatt A. "Intravesical therapy for recurrent urinary tract infection: a systematic review and meta-analysis." BJU Int. 2026. doi:10.1111/bju.70252